Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwartz, L. H.
Right arrow Articles by Panicek, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwartz, L. H.
Right arrow Articles by Panicek, D. M.

Radiology, Vol 208, 735-738, Copyright © 1998 by Radiological Society of North America

ARTICLES

Small cell and anaplastic prostate cancer: correlation between CT findings and prostate-specific antigen level

LH Schwartz, LR LaTrenta, E Bonaccio, WK Kelly, HI Scher and DM Panicek
Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

PURPOSE: To evaluate the computed tomographic (CT) findings in patients with the anaplastic clinical variant of prostate cancer and to correlate these with prostate-specific antigen (PSA) levels. MATERIALS AND METHODS: Twenty-seven men with the anaplastic clinical variant of prostate cancer, including 12 patients with small cell cancer of the prostate, underwent CT before platinum-based chemotherapy. CT findings were retrospectively reviewed for the extent of disease in the abdominal and pelvic lymph nodes, liver, bone, and prostate. CT findings were correlated with baseline PSA levels. RESULTS: The overall mean PSA level was 59.9 ng/ml +/- 23.3 (range, 0-583 ng/ml; median, 4 ng/ml), with a mean PSA level in the small cell cancer subgroup of 12.3 ng/ml +/- 9.0 (range, 0-110 ng/mL; median, 1.7 ng/mL). Twenty-six patients (96%) had metastatic disease evident at CT, but only nine (33%) had PSA levels greater than 10 ng/mL. The mean PSA level in patients with pelvic lymphadenopathy was 12.8 ng/mL +/- 7.9 (median, 1.6 ng/mL); that in the small cell cancer subgroup was only 2.8 ng/ml +/- 1.4 (median, 1.6 ng/ml). Whereas 19 (70%) of all patients had osseous metastases and an average PSA level of 73 ng/ml +/- 32(median, 9.1 ng/mL), the seven (58%) with small cell cancer and bone metastases had an average PSA level of 18 ng/mL +/- 13 (median, 4 ng/mL). CONCLUSION: Unlike patients with advanced typical adenocarcinoma of the prostate, patients with the anaplastic clinical variant of prostate cancer often have extensive metastatic disease at CT despite relatively low PSA levels.


This article has been cited by other articles:


Home page
 Br. J. Radiol.Home page
J M CHANG, H J LEE, S E LEE, S-S BYUN, G Y CHOE, S H KIM, C K SEONG, and S H KIM
Unusual tumours involving the prostate: radiological-pathological findings
Br. J. Radiol., November 1, 2008; 81(971): 907 - 915.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1998 by the Radiological Society of North America.